Annotation Detail

Information
Associated Genes
RRM1
Associated Variants
RRM1 UNDEREXPRESSION ( ENST00000300738.10 )
RRM1 UNDEREXPRESSION ( ENST00000300738.10 )
Associated Disease
pancreatic cancer
Source Database
CIViC Evidence
Description
In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG. Analysis for identifying genetic alterations relating to gemcitabine resistance revealed that RRM1 was the most upregulated gene with a 4.5 fold expression. RRM1-specific RNAi transfection significantly reduced the gemcitabine chemoresistance of MiaPaCa2-RG to the same level as that of gemcitabine sensitive MiaPaCa2. Moreover, gemcitabine response of MiaPaCa2 also became more sensitive. Next, patients with pancreatic cancer were recruited and 18 tissue samples were taken. The patients with a low RRM1 expression had a significantly better outcome after gemcitabine treatment than those patients with high RRM1 expression (P=0.016).
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/5508
Gene URL
https://civic.genome.wustl.edu/links/genes/5051
Variant URL
https://civic.genome.wustl.edu/links/variants/1257
Rating
3
Evidence Type
Predictive
Disease
Pancreatic Cancer
Evidence Direction
Supports
Drug
Gemcitabine
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
17131328
Drugs
Drug NameSensitivitySupported
GemcitabineSensitivitytrue